A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

Table 4 Clinical and immunological outcome

Patient	Cycles received	Off-therapy reason	Off-study status	PFS	OS	Immune response
1	2	P	P	2	17	Neg
2	10	PSC	NED	88 +	88 +	Pos
3	6	R	R	6.5	87 +	Pos
4	4	P	P	4	8	Pos
5	11	PSC	R	13.5	30.5	Neg
6	18	PSC	S	57 +	57 +	Pos

Abbreviations: P = progressive disease; R = recurrent disease; S = stable disease; NED = no evidence of disease; PSC = peptide stock completed; PFS = progression-free survival in months; OS = overall survival in months (both PFS and OS were calculated from the on-study date until progression, death, or last known follow-up marked as (+); Pos = positive immune response; Neg = negative immune response.

ISSN: 1479-5876